MedTrace Logo

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2019-05-07

Study results available
· View outcomes & findings →

Summary

The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD

Conditions

  • ADHD

Interventions

DRUG

Placebo

Oral placebo capsule

DRUG

PRC-063 25 mg

Oral 25 mg capsule - active

DRUG

PRC-063 45 mg

Oral 45 mg capsule - active

DRUG

PRC-063 70 mg

Oral 70 mg capsule - active

DRUG

PRC-063 100 mg

Oral 100 mg capsule - active

Sponsors & Collaborators

  • Purdue Pharma, Canada

    collaborator INDUSTRY

  • Rhodes Pharmaceuticals, L.P.

    lead INDUSTRY

Principal Investigators

  • Joseph Reiz · Purdue Pharma LP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-10-31
Completion
2015-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139124 on ClinicalTrials.gov